von Willebrand Factor

Subscribe to Selected New Research on von Willebrand Factor

3773 relevant articles (75 outcomes, 355 trials/studies) found for this Bio-Agent

Description: A high-molecular-weight plasma protein, produced by endothelial cells and megakaryocytes, that is part of the factor VIII/von Willebrand factor complex. The von Willebrand factor has receptors for collagen, platelets, and ristocetin activity as well as the immunologically distinct antigenic determinants. It functions in adhesion of platelets to collagen and hemostatic plug formation. The prolonged bleeding time in von Willebrand's disease is due to the deficiency of this factor.

Also Known As:

F VIII-vWf; Factor VIIIR-Ag; Factor VIIIR-RCo; Plasma Factor VIII Complex; Ristocetin Cofactor; Ristocetin-Willebrand Factor; vWF Ag; von Willebrand Factor Type IIB; von Willebrand Protein; Ag, vWF; Antigen, Factor VIII-Related; Cofactor, Ristocetin; F VIII vWf; Factor VIII Related Antigen; Factor VIIIR Ag; Factor VIIIR RCo; Protein, von Willebrand; Ristocetin Willebrand Factor; Factor VIII-Related Antigen

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Meyer, D: 15 articles (05/2008 - 01/2000)
2.	Lip, Gregory Y H: 14 articles (05/2008 - 07/2002)
3.	Blann, A D: 14 articles (04/2007 - 01/2001)
4.	Federici, A B: 11 articles (05/2008 - 12/2000)
5.	Lip, G Y H: 10 articles (04/2007 - 02/2002)
6.	Casonato, A: 8 articles (09/2008 - 01/2001)
7.	Lenting, Peter J: 8 articles (09/2008 - 03/2004)
8.	Mazurier, C: 8 articles (05/2008 - 02/2001)
9.	Budde, U: 8 articles (05/2008 - 03/2000)
10.	Mannucci, P M: 8 articles (05/2008 - 01/2000)

Related Diseases

1.	von Willebrand Disease (von Willebrand's Disease) 07/01/2007 - "BACKGROUND: While plasma-derived concentrates containing large amounts of von Willebrand factor (VWF) are effective in treating von Willebrand disease (VWD), optimal dosing remains to be fully characterized. " 01/01/1995 - "The definition of the molecular basis of von Willebrand's disease has helped clarify the structure of von Willebrand factor as well as its essential role in platelet function, particularly under haemodynamic conditions of high shear stress. " 02/01/2006 - "Increased clearance of von Willebrand factor (VWF) is one of the main features of type Vicenza von Willebrand disease (VWD), a variant with plasma and platelet VWF level discrepancies and unusually large VWF multimers. " 02/01/2007 - "BACKGROUND: von Willebrand disease (VWD) type 2 is associated with mutations in von Willebrand factor (VWF) that affect its secretion, multimeric pattern, affinity for platelet receptors and clearance of the protein. " 01/01/2006 - "The efficacy of the two von Willebrand factor (vWF) intron 40 variable number of tandem repeat (VNTR) markers, vWF1 and vWF2, in the genetic diagnosis of von Willebrand disease (vWD) in Indian patients was studied. " Order ALL the reference details at left...
2.	Hemorrhage 09/01/2008 - "SUMMARY: Given the relatively high proportion of defects noted, after an initial assessment by the bleeding score, testing up-front should include von Willebrand factor analysis, and if normal, platelet aggregation and release studies should follow." 10/01/2003 - "Several studies have evaluated von Willebrand factor in normal pregnancy, but none considered the personal history of bleeding. " 01/01/1995 - "The present study reports on the sensitivity of the in vitro bleeding test (IVBT) in 51 vWD cases of different types and severity in comparison to the Simplate BT, and the correlation of both to each other as well as to von Willebrand factor (vWF:RCo) activity. " 07/01/1992 - "Family studies revealed that his mother has mild bleeding symptoms, decreased VIIIC, vWF:Ag, and RCof levels and normal to slightly reduced RIPA with a multimer pattern consistent with type I vWD. " 06/01/1989 - "In order to provide an overview of the relative contribution of platelet, von Willebrand factor, and other abnormalities to patients with clinical bleeding difficulties, we performed a retrospective survey of coagulation studies on 569 individuals referred to the University of Manitoba coagulation laboratory because they, or a closely related family member, showed clinical evidence of a bleeding disorder. " Order ALL the reference details at left...
3.	Hemophilia A (Haemophilia) 01/01/1985 - "In addition, these studies suggest that there may be significant differences in the factor VIII-related antigen (VIII R:Ag) on platelets in haemophilia A patients compared to normal." 03/01/2008 - "A retrospective chart review of 11 subjects with severe haemophilia A and high-titre inhibitors who received a von Willebrand factor-containing FVIII concentrate (VWF/FVIII) for immune tolerance induction (ITI) was accompanied by B cell inhibitor epitope mapping during 10/11 treatment courses. " 03/01/2008 - "In addition, von Willebrand factor activity, determined by the human platelet aggregation test, was within the normal range; therefore, the calf was diagnosed with hemophilia A. " 07/01/2007 - "Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response." 04/01/2004 - "Hemophilia A: role of FVIIIC/vWF Ag in assisting linkage analysis for carrier detection." Order ALL the reference details at left...
4.	Thrombotic Thrombocytopenic Purpura 09/01/2005 - "The demonstration that a severe deficiency of von Willebrand factor-cleaving protease activity in acquired thrombotic thrombocytopenic purpura is due to an autoantibody inhibitor of the von Willebrand factor-cleaving protease argues for targeting the antibody inhibitor of the von Willebrand factor-cleaving protease with immunosuppressive therapy as a means of increasing protease activity and inducing a sustained remission of the disease. " 06/01/2009 - "The active conformation of von Willebrand factor in patients with thrombotic thrombocytopenic purpura in remission." 01/01/1992 - "Chronic relapsing thrombotic thrombocytopenic purpura in infants with large von Willebrand factor multimers during remission." 01/01/2006 - "Recent studies demonstrate that severe deficiency of the von Willebrand factor cleaving metalloprotease, ADAMTS 13, causes thrombotic thrombocytopenic purpura. " 11/30/2005 - "[A study on the significance of plasma thrombospondin1 in thrombotic thrombocytopenic purpura and the relationship between thrombospondin1 and von Willebrand factor cleaving protease (ADAMTS13)]" Order ALL the reference details at left...
5.	Thrombosis (Thrombus) 06/01/2009 - "More over, in an in vitro study when whole blood was circulated both at venous and arterial shear conditions and shear rate was adjusted according to the blood viscosity, platelet aggregate/thrombus formation was characteristic on surfaces covered with purified von Willebrand factor while in case of controls the surface was covered with single platelets or platelet monolayer. " 07/01/2007 - "The recognition of VWD as a distinct entity in blood and the cloning of the von Willebrand factor (VWF) gene in the 1980s encouraged both phenotypic and genotypic studies, culminating in 1994 with the recognition, by the VWF subcommittee of the Scientific and Standardization Committee (SSC) of International Society of Thrombosis and Haemostasy (ISTH), of three types of VWD, characterized by severe plasma VWF deficiency (type 3), functionally deficient plasma VWF (type 2) and reduced (below normal) levels of plasma VWF, which is functionally essentially normal (type 1; 70% of all cases). " 05/17/2002 - "The purpose of this study was to investigate the antithrombotic effect and bleeding time prolongation of AJW200, a humanized monoclonal antibody to von Willebrand factor (vWF), in a canine model of coronary arterial thrombosis. " 11/01/2009 - "ADAMTS13 may play a role in arterial thrombosis by cleaving the highly active and thrombogenic ultralarge Von Willebrand Factor (VWF) multimers into less active VWF multimers. " 07/01/2009 - "BACKGROUND: von Willebrand factor (VWF) has a role in both hemostasis and thrombosis. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Factor VIII (Coagulation Factor VIII)
2.	Antigens
3.	von Willebrand Factor
4.	thymidine 5'-triphosphate (TTP)
5.	Collagen
6.	Deamino Arginine Vasopressin (Desmopressin)
7.	C-Reactive Protein
8.	Fibrinogen (Factor I)
9.	Tissue Plasminogen Activator (Alteplase)
10.	Factor VII (Proconvertin)

Related Therapies and Procedures

1.	Plasma Exchange
2.	Homologous Transplantation (Allograft)
3.	Prostheses and Implants (Prosthesis)
4.	Transplants (Transplant)
5.	Peritoneal Dialysis

Best Treatments:
Research Summary Report
on von Willebrand Disease

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 61 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>